Vanguard Portfolio Management
VKTX icon

Vanguard Portfolio Management’s Viking Therapeutics VKTX Stock Holding History

Vanguard Portfolio Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175M Buy
4,484,263
+19,965
+0.4% +$645K 0.01% 1282
2026
Q1 		$145M Buy
+4,464,298
New +$143M 0.01% 1298

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management's VKTX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Viking Therapeutics (VKTX) stake by 0.45% in Q2 2026, buying an estimated $645K and bringing the position to 4,484,263 shares worth $175M. The position accounts for 0.01% of the portfolio, ranked #1282.

Vanguard Portfolio Management first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 431 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Vanguard Portfolio Management held 4,484,263 shares of Viking Therapeutics worth $175M as of Q2 2026.
  • Vanguard Portfolio Management bought 19,965 Viking Therapeutics shares in Q2 2026, an estimated $645K.
  • Viking Therapeutics made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1282 holding.
  • Vanguard Portfolio Management first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 431 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.